On November 10, 2017 MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, reported that five posters based on the Company’s PD-1-directed franchise will be presented at the 2017 Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting in National Harbor, MD (Press release, MacroGenics, NOV 10, 2017, View Source [SID1234521925]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Posters will be displayed in the poster hall both Friday, November 10 and Saturday, November 11. Presentation details are provided below:
MGA012 (anti-PD-1 monoclonal antibody):
P249: "A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics (PK) of MGA012 (anti‐PD‐1 Antibody) in Patients with Advanced Solid Tumors"
P336: "Preclinical Characterization of MGA012, a Novel Clinical‐stage PD‐1 Monoclonal Antibody"
MGD013 (PD-1 x LAG-3 bispecific DART molecule):
P244: "A Phase 1, First‐in‐Human, Open‐label, Dose Escalation Study of MGD013, a Bispecific DART Protein Binding PD‐1 and LAG‐3 in Patients with Unresectable or Metastatic Neoplasms"
P337: "Preclinical Characterization of MGD013, a PD‐1 x LAG‐3 Bispecific DART Molecule"
MGD019 (PD-1 x CTLA-4 bispecific DART molecule):
P308: "A PD‐1 x CTLA‐4 Bispecific DART Protein with Optimal Dual Checkpoint Blockade and Favorable Tolerability in Non-human Primates"
The above posters are available for download from the Events & Presentations page on MacroGenics’ website at View Source